Stryker Co. (NYSE:SYK) Shares Acquired by Davis R M Inc.

Davis R M Inc. increased its position in Stryker Co. (NYSE:SYK) by 7.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 133,017 shares of the medical technology company’s stock after acquiring an additional 9,057 shares during the period. Davis R M Inc.’s holdings in Stryker were worth $47,893,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Independent Advisor Alliance grew its holdings in Stryker by 19.4% during the 4th quarter. Independent Advisor Alliance now owns 8,149 shares of the medical technology company’s stock valued at $2,934,000 after buying an additional 1,325 shares during the last quarter. Paragon Private Wealth Management LLC grew its holdings in Stryker by 12.6% during the 4th quarter. Paragon Private Wealth Management LLC now owns 1,258 shares of the medical technology company’s stock valued at $453,000 after buying an additional 141 shares during the last quarter. Johnson Investment Counsel Inc. grew its holdings in Stryker by 6.5% during the 4th quarter. Johnson Investment Counsel Inc. now owns 176,956 shares of the medical technology company’s stock valued at $63,713,000 after buying an additional 10,856 shares during the last quarter. Daiwa Securities Group Inc. grew its holdings in Stryker by 5.9% during the 4th quarter. Daiwa Securities Group Inc. now owns 51,886 shares of the medical technology company’s stock valued at $18,682,000 after buying an additional 2,883 shares during the last quarter. Finally, NBT Bank N A NY grew its holdings in Stryker by 20.1% during the 4th quarter. NBT Bank N A NY now owns 4,240 shares of the medical technology company’s stock valued at $1,527,000 after buying an additional 709 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Down 2.7 %

Shares of SYK opened at $369.16 on Tuesday. The stock’s fifty day simple moving average is $382.59 and its 200 day simple moving average is $373.31. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The firm has a market capitalization of $140.87 billion, a P/E ratio of 47.57, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the firm earned $3.46 EPS. On average, equities research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Analysts Set New Price Targets

A number of brokerages have commented on SYK. Citigroup reiterated a “buy” rating and set a $450.00 target price on shares of Stryker in a report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and set a $442.00 target price on shares of Stryker in a report on Wednesday, January 29th. Barclays increased their price target on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Royal Bank of Canada increased their price target on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 29th. Finally, Truist Financial increased their price target on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research note on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $421.90.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.